Emily Culme-seymour PhD

Emily is External Strategy Manager, Gene Therapy in GSK’s Rare Diseases Unit. She works as a scientist looking at developing external relationships and partnerships in the field, as well as providing scientific guidance and input to the internal gene therapy strategy and pipeline. Emily has a background in Chemistry and Biochemical Engineering, looking at engineering growth substrates for pluripotent stem cell bioprocessing during her PhD at University College London, UK (2006-2010). She currently sits on the International Society for Cell Therapy’s Executive Committee as Global Treasurer and on the American Society for Gene and Cell Therapy’s International Committee, and is a member of the UK BioIndustry Association’s Cell and Gene Therapy Advisory Committee, the Alliance for Regenerative Medicine Gene and Gene-Modified Cell Therapy Section, and both the European and British Societies for Gene and Cell Therapy.